Pharvaris publishes review on bradykinin B2 receptor as therapy target

Pharvaris (Nasdaq: PHVS), a biopharmaceutical company based in Zug, Switzerland, announced the publication of a review article in Clinical Reviews in Allergy & Immunology examining the role of the bradykinin B2 receptor in bradykinin-mediated angioedema and related conditions.

The article summarizes decades of scientific and clinical research on bradykinin B2 receptor antagonism as a therapeutic approach for conditions including hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). It also reviews evidence suggesting bradykinin signaling may play a role in broader immunological and inflammatory disorders such as bronchial asthma, chronic cough, allergic rhinitis, and chronic urticaria.

Anne Lesage, Ph.D., Chief Early Development Officer of Pharvaris, stated: "The long history of scientific and clinical evidence demonstrates that bradykinin B2 receptor antagonism is a validated and foundational therapeutic approach in the management of bradykinin-mediated angioedema."

Lesage added that to date, "there have been no observations of increased risks of long-term unfavorable effects from the antagonism of the bradykinin B2 receptor."

The review traces the development of bradykinin B2 receptor antagonism from foundational discoveries in kinin biology to its current clinical applications. The article notes that by blocking the receptor through which bradykinin exerts pathological effects, this class of antagonists targets the mechanism of swelling regardless of the upstream cause of excess bradykinin production.

Pharvaris is developing oral bradykinin B2 receptor antagonists and has ongoing late-stage clinical trials, including studies for the on-demand treatment of acute HAE attacks.

You May Also Be Interested In

• FDA issues early alert on Boston Scientific catheter tip separation risk
• Elme Communities cuts liquidating distribution estimate after Riverside deal
• Tianci International sets up Zimbabwe unit for chromium operations